Active	Status	Sponsor type	Region	Phase	Filter
9 Active 6 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dreyling, Martin
NCT01788020 / 2013-000506-37: Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia	Completed	3	202	Europe	Dexamethasone, Rituximab, Cyclophosphamide, Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib	University of Ulm, Centre Hospitalier de Lens (Co-Sponsor)	Waldenström's Macroglobulinemia	11/18	04/24
MCL R2, NCT01865110 / 2012-002542-20: R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL	Active, not recruiting	3	623	Europe	R-CHOP, rituximab, CHOP, R-CHOP / R-HAD, rituximab HD AraC, Rituximab, Mabthera, Lenalidomide, Revlimid	The Lymphoma Academic Research Organisation	Mantle Cell Lymphoma	11/20	08/25
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Active, not recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	12/25	07/26
FORTplus, NCT05045664: Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody	Recruiting	3	100	Europe	Standard, Experimental, Rituximab, Obinutuzumab	Heidelberg University	Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a	12/26	12/29
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia	Recruiting	2/3	210	Europe	Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA	University of Giessen	Hairy Cell Leukemia	12/25	12/27
CARMAN, NCT06482684: CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma	Recruiting	2	150	Europe	KTE-X19, Ibrutinib	Christian Schmidt, MD, Johannes Gutenberg University Mainz	Mantle Cell Lymphoma	06/31	12/31
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients	Active, not recruiting	2	36	Europe	Copanlisib, Aliqopa, Rituximab, Truxima	Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer	Marginal Zone Lymphoma	06/24	12/29
Lindemann, H W
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia	Recruiting	2/3	210	Europe	Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA	University of Giessen	Hairy Cell Leukemia	12/25	12/27